

Parenteral Cytotoxic Chart

Patient Details

Forename

Surname

Protocol

DOB

Patient NO

Local No.

Course Name:

Consultant

Ward

Type of line

NHS No

AXITINIB

Axitinib

Diagnosis

SA (m²)

Height (m)

Weight (kg)

Prostatic carcinoma

Monitoring	Acceptable Range		Date Due	Date of Test	Value	Checked
Height (m)						
Weight (kg)						
SA (m²)						
BILIRUBIN 1.5ULN	0.00	31.50	Day [1]			
Cockcroft >15mls/min	15.00	300.00	Day [1]			
NEUTROPHILS > 1.5	1.50	15.00	Day [1]			
PLATELETS > 100	100.00	600.00	Day [1]			

Additional Prescribing Notes

Patients MUST be registered with the CDF before commencing treatment.

Take orally twice daily approximately 12 hours apart with or without food and should be swallowed whole with a glass of water.

The dose of axitinib may be increased- refer to SPC

Mild Hepatic Impairment (Child Pugh Class A) - No dose adjustment
Moderate Hepatic Impairment (Child Pugh Class B) - Reduce to Axitinib 2mg BD
Severe Hepatic Impairment (Child Pugh C) - Discontinue

Allocated by:

Confirmed by:

Authorised by:

Checked by: (Pharmacist)

Date:

Date:

Date:

Date:

Chart Id.:

Parenteral

Intrathecal

Oral

1

0

1

Patient Details

Forename	Surname		Protocol	AXITINIB					SA (m²)				
			Course Name	Axitinib					Height (m)				
DOB	Patient NO		Local No.		NHS No							Weight (kg)	
Consultant			Ward		Diagnosis		Prostatic carcinoma						
Address													

Record drug allergies or sensitivities

				Time	Date													
Drug & dose	AXITINIB																	
Actual dose	5 mg		Duration	28 DAYS														
Route	PO		Start Date															
Frequency	BD		Start Day	1														
Quantity Dispensed			Dispensed by															
			Accuracy check															
Note	Patients MUST be registered with the CDF before commencing treatment.																	

Allocated by:	Confirmed by:	Authorised by:	Checked by: (Pharmacist)	Chart Id.:
Date:	Date:	Date:	Date:	
/ /	/ /	/ /	/ /	